drug
as of 2026-07-01Lu AF11167
at a glance
small molecule
Pre-approval / investigational in the US
Developed by H. Lundbeck A/S
3 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
3
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
NCT03929497Phase 2Terminated
Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167
NCT02260830Phase 1Completed
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
NCT02202213Phase 1Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication